Home Services
Genomic Test
Prodia for Doctor
Prodia Successfully Achieved Net Profit of IDR 159.8 Billion in Semester I of 2022 With Digital Transformation
The statement of financial position in the first semester of 2022 recorded the Company's total current assets of Rp 1,474.7 billion with total non-current assets of Rp 972.1 billion.
JAKARTA, 29 July 2022 – PT Prodia Widyahusada, Tbk. (stock code: PRDA) achieved positive financial performance for the first semester of this year with the Company's net profit of Rp 159.8 billion. This performance was supported by sales figure of Rp 1,037.0 billion and operating profit of Rp 188.8 billion. This optimal performance is carried out because of the optimal work of all Insan Prodia and the innovation strategies carried out, including the implementation of digital transformation.
The statement of financial position in the first semester of 2022 recorded the Company's total current assets of Rp 1,474.7 billion with total non-current assets of Rp 972.1 billion. Therefore, compared to the position of the Financial Statements as of December 31, 2021, the total assets of the Company were recorded at Rp 2,446.8 billion, a slight decrease of 10.0%. Meanwhile, total short-term liabilities were recorded at Rp 203.8 billion, and long-term liabilities were recorded at Rp 199.8 billion, bringing the Company's total liabilities to a correction to Rp 403.6 billion. Total equity was recorded at Rp 2,043.1 billion, bringing the Company's total liabilities and equity to a correction of Rp 2,446.8 billion.
In the first semester of 2022, the corrected revenue was accompanied by a relatively stable cost of goods compared to last year, resulting in the Company's gross profit of Rp 627.2 billion. The Company's operating expenses in the first semester of 2022 increased to Rp 439.2 billion so that the Company's operating profit was recorded at Rp 188.8 billion. The Company's income tax expense decreased to Rp 41.5 billion, therefore, the Company's net profit earned in the first semester of 2022 was recorded at Rp 159.8 billion. The company still has a solid performance, although there have been some normalizations in performance this year.
The cash flow statement for the first semester of 2022 recorded operating activities of Rp 165.0 billion and cash flow from investing activities of Rp 40.1 billion. Cash flow from financing activities increased to negative Rp 374.3 billion when compared to the first semester of 2021, which was negative Rp 165.0 billion. Therefore, the Company's cash and cash equivalents in the first semester of 2022 were recorded at Rp 438.7 billion, higher than the cash and cash equivalents in the first semester of 2021 which amounted to Rp 473.3 billion. The Company's financial position is still very healthy and strong to finance the Company's business and operational activities until the end of the 2022 financial year.
Prodia's President Director, Dewi Muliaty, explained, "In the midst of uncertainty of the global situation that affects the economic movement of people in Indonesia, the Company still maintains a stable performance. The Company strives to always optimize good performance in the midst of a today’s dynamic situation, namely global inflation and the ongoing COVID-19 pandemic. The importance of the role of Insan Prodia in building the trust of customers is the basic foundation for the Company to develop and grow. We strive to consistently improve performance and services, and continue to innovate in order to maintain a sustainable health ecosystem in Indonesia, so that Prodia can maintain its existence as the best and leading private health service in Indonesia.”
To support the Company's performance, Prodia continues to encourage the implementation of Digital Transformation, such as the development of Prodia Mobile App which is now equipped with Home Service, which also supports the performance of the first semester of 2022. The Company recorded a significant increase of around 188.4% of Prodia Mobile App downloaders compared to the previous year. Total Mobile App revenue increased by 245.1% in line with the increase in the number of orders via Mobile App by 244.6%. The Home Service also recorded a very good performance with a revenue growth of 101.9% and a growth in the number of visits by 129.9% in this first semester of 2022.
rodia's Digital Transformation efforts also won the 2022 Top Digital Company Award for the Laboratory category, which was awarded by Marketing magazine in collaboration with Survey One as an independent research agency. This award is the third time that Prodia has received, proving Prodia's commitment to the development of digital-based services to provide a more comprehensive customer experience. Especially in times of pandemic instability, Prodia continues to provide digital innovations in giving healthcare services to the customers.
Digital service innovation is a form of Prodia's commitment in providing superior customer experience in the pandemic era. Superior service that adapts to customer needs has made Prodia also won the 2022 Service Quality Awards for the Clinical Laboratory category. This brilliant achievement is a high token of appreciation for Prodia that the hard work of Insan Prodia in providing the best service to customers and responding to customer needs in a responsive, personal, and professional manner.
Among the efforts of various industries to maintain their existence during this on-going pandemic, the digitization of services and products is the main key in business strategy, and Prodia is no exception. This is what made Prodia successful in winning the Indonesia Digital Popular Brand Award 2022 organized by Infobrand in the first half of 2022. Prodia's digital innovations as an adaptive step in responding to challenges and dynamics in the pandemic era have strengthened Pro ia as the best and most trusted brand for customers in Indonesia.
******
About PT Prodia Widyahusada Tbk
Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Andi Wijaya, along with the other founders have been committed to present the best test results with wholehearted services.
As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that Prodia' s test results are equal in quality to those obtained from other international laboratories.
On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol 'PRDA'. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company' s initial public offering (IPO) was IDR1.22 billion.
Currently, Prodia has had the service network that incorporates 263 outlets, across 127 cities and 34 provinces in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children' s Health Centre (PCHC), Prodia Women' s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).
Prodia has launched Kontak Prodia 1500-830 and the online-based virtual personal assistant Tanya Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers directly anytime and anywhere online including via LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id and Prodia Website: www.prodia.co.id.
For more information, please visit www.prodia.co.id or contact:
Marina Eka Amalia Legal Head & Corporate Secretary | Magdalena Vandry Investor Relation Head |